Patent ID: 6881396

Claim:
A composition comprising: (1) a radiopharmaceutical precursor comprising a targeting moiety selected from the group consisting of an antibody, a Fab antibody fragment, a F(ab)′ 2 antibody fragment, an epitope binding complementarity determining region derived from an antibody, a peptide, a growth factor, a receptor binding fragment of a growth factor, a hormone, a steroid, a receptor binding nucleic acid, a receptor binding monosaccharide, a receptor binding disaccharide, a receptor binding oligosaccharide, a receptor-binding lipid, a receptor binding benzodiazepine and a receptor binding antibiotic; and (2) a stabilizing amount of a hydrophilic 6-hydroxy-chroman derivative of the formula: wherein one of Y and Z is selected from the group consisting of O, S, C═O, and (CHR 3 ) n , where n is an integer from 0 to 3, and the other of Y and Z is selected from the group consisting of C═O and (CHR 3 ) n where n is an integer from 0 to 3; each R 3 group is independently selected from the group consisting of H, alkyl, halogen, —OR 4 , —SO 3 H, —SO 3 R 4 , —S(O) m R 4 , —COOR 4 , —NO 2 , —CONH m (R 4 ) 2-m , —NH m (R 4 ) 2-m , —COR 4 , —CH 2 OR 4 , —COR 5 , —SO 2 NH m (R 4 ) 2-m , —R 5 , and —CH 2 R 5 , where m is an integer from 0 to 2; R 4 is H or C 1 to C 3 alkyl; and R 5 is selected from the group consisting of a monosaccharide, disaccharide, and a hydrophilic peptide sequence of up to 5 amino acids comprising at least one hydrophilic amino acid residue.